Merck KGaA 2010 Results Marred By Cladribine And Poor OTC Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Millipore acquisition boosts 2010 results for Germany's Merck, but pharma strategy remains unclear.
You may also be interested in...
Merck KGaA Chairman Karl-Ludwig Kley Says Industry Model Not Broken: An Interview With PharmAsia News (Part 2 of 2)
Merck KGaA Global Chariman Karl-Ludwig Kley, while soft-spoken, is fiercely determined to make a lasting impact for stakeholders. Kley contradicts commonly expressed views within the pharma industry on the challenges confronting the industry. At 60, Kley has gathered vast experience across industries having worked at Siemens AG before moving into the pharmaceutical industry with a job at Bayer AG back in 1982. In 2006, Kley joined Merck and a year later he was appointed as its Chairman. On his recent visit to India, he spoke to PharmAsia News' India Bureau on a range of subjects related to the global industry and the shape of emerging markets. In part one of this interview, Kley discussed challenges facing the industry and the role that emerging markets can play. In this second part, he discusses Merck KGaA's pipeline and how the company is positioning itself on the global stage.
Merck KGaA Pins Cladribine Hopes On Ongoing Studies After Complete Response Letter
The oral MS therapy adds the FDA rebuff to a January EU rejection; both regulatory bodies want to get a better fix on the drug's risk/benefit profile.
Merck KGaA Pins Cladribine Hopes On Ongoing Studies After Complete Response Letter
The oral MS therapy adds the FDA rebuff to a January EU rejection; both regulatory bodies want to get a better fix on the drug's risk/benefit profile.